Summary
The bioreductive drug tirapazamine (TPZ, SR 4233, WIN 59075) is a lead compound in a series of potent cytotoxins that selectively kill hypoxic rodent and human solid tumour cells in vitro and in vivo. Phases II and III trials have demonstrated its efficacy in combination with both fractionated radiotherapy and some chemotherapy. We have evaluated the generality of an enzyme-directed approach to TPZ toxicity by examining the importance of the one-electron reducing enzyme NADPH:cytochrome P450 reductase (P450R) in the metabolism and toxicity of this lead prodrug in a panel of seven human non-small-cell lung cancer cell lines. We relate our findings on TPZ sensitivity in these lung lines with our previously published results on TPZ sensitivity in six human breast cancer cell lines (Patterson et al (1995) Br J Cancer 72: 1144–1150) and with the sensitivity of all these cell types to eight unrelated cancer chemotherapeutic agents with diverse modes of action. Our results demonstrate that P450R plays a significant role in the activation of TPZ in this panel of lung lines, which is consistent with previous observations in a panel of breast cancer cell lines (Patterson et al (1995) Br J Cancer 72: 1144–1150; Patterson et al (1997) Br J Cancer 76: 1338–1347). However, in the lung lines it is likely that it is the inherent ability of these cells to respond to multiple forms of DNA damage, including that arising from P450R-dependent TPZ metabolism, that underlies the ultimate expression of toxicity.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adams, GE & Stratford, IJ (1986). Hypoxia-mediated nitro-heterocyclic drugs in the radio and chemotherapy of cancer: an overview. Biochem Pharmacol 35: 71–78.
Adams, GE & Stratford, IJ (1994). Bioreductive drugs for cancer therapy: the search for tumour specificity. Int J Radiat Oncol Biol Phys 29: 231–238.
Arteel, GE, Thurman, RG & Raleigh, JA (1998). Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 253: 743–750.
Barham, HM, Patterson, AV, Chinje, EC, Harris, AL & Stratford, IJ (1995). Sensitivity to tirapazamine (SR 4233) is determined by P450 reductase in human breast but not lung cancer cell lines. Br J Cancer 71: 20
Biaglow, JE, Jacobson, B, Greenstock, CL & Raleigh, J (1977). Mol Pharmacol 13: 262
Biedermann, KA, Wang, J, Graham, RP & Brown, JM (1991). SR 4233 cytotoxicity and metabolism in DNA repair-competent and DNA repair-deficient cell cultures. Br J Cancer 63: 358–362.
Brown, JM (1993). SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163–1170.
Brown, JM & Lemmon, MJ (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745–7749.
Brown, JM & Lemmon, MJ (1991). Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20: 457–461.
Cahill, A & White, INH (1990). Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis 11: 1407–1411.
Carmichael, J, De Graff, WG, Gazdar, AF, Minna, JD & Mitchell, JB (1987). Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936–941.
Chinje, EC, Saunders, MP, Patterson, AV, Harris, AL & Stratford, IJ (1998). Using gene therapy to determine the mechanism of hypoxic activation of tirapazamine. B J Cancer 78 S1: P27
Costa, AK, Baker, MA, Brown, JM & Trudell, JR (1989). In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res 49: 925–929.
Dorie, MJ & Brown, JM (1993). Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633–4636.
Durand, RE (1994). The influence of microenvironmental factors during cancer therapy. In vivo 8: 691–702.
Elwell, JH, Siim, BG, Evans, JW & Brown, JM (1997). Adaptation of human tumor cells to tirapazamine under aerobic conditions: Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol 54: 249–257.
Evans, JW, Yudoh, K, Delahoussaye, YM & Brown, JM (1998). Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58: 2098–2101.
Fitzsimmons, SA, Lewis, AD, Riley, RJ & Workman, P (1994). Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15: 1503–1510.
Gatenby, RA, Kessler, HB, Rosenblum, JS, Coia, LR, Moldofsky, PJ, Hartz, WH & Bbroder, GJ (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to the outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831–838.
Hockel, M, Knoop, C, Schlenger, K, Vorndran, B, Baussman, E, Mitze, M, Knapstein, PG & Vaupel, P (1993). Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45–50.
Houlbrook, S, Kirk, J, Stuart, NSA, Stratford, IJ, Harris, AL, Pettit, GR & Carmichael, J (1994). Human tumour cell lines: a valuable model for evaluating new drugs and the mechanism underlying cytotoxic drug resistance. Oncol (Life Sci Adv) 13: 69–76.
Jones, DP (1981). Hypoxia and drug metabolism. Biochem Pharmacol 30: 1019–1023.
Kim, IH & Brown, JM (1994). Reoxygenation and rehypoxiation in SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 29: 493–497.
Koch, CJ (1993). Unusual oxygen concentration dependence of toxicity of SR 4233, a hypoxic cell toxin. Cancer Res 53: 3992–3997.
Lloyd, RV, Duling, DR, Rumyantseva, GV, Mason, RP & Bridson, PK (1991). Microsomal reduction of 3-amino-1,24-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 40: 440–445.
Mossman, T (1983). Rapid colorimetric assay for the cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–61.
Nordsmark, M, Overgaard, M & Overgaard, J (1996). Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiather Oncol 41: 31–40.
Okunieff, P, Hoeckel, M, Dunphy, EP, Schlenger, K, Knoop, C & Vaupel, P (1993). Oxygen tension distributions are sufficient to explain the local response of human breast tumours treated with radiation alone. Int J Radiat Oncol Biol Phys 26: 631–636.
Patterson, AV, Barham, HM, Chinje, EC, Adams, GE, Harris, AL & Stratford, IJ (1995). Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72: 1144–1150.
Patterson, AV, Saunders, MP, Chinje, EC, Talbot, DC, Harris, AL & Stratford, IJ (1997). Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76: 1338–1347.
Patterson, AV, Saunders, MP, Chinje, EC, Patterson, LH & Stratford, IJ (1998). Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Design 13: 541–573.
Plumb, JA, Milroy, R & Kaye, SB (1989). Effects of the pH dependence of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49: 4435–4440.
Riley, RJ & Workman, P (1992). Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem Pharmacol 43: 167
Riley, RJ, Hemingway, SA, Graham, MA & Workman, P (1993). Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem Pharmacol 45: 1065
Robertson, N, Haigh, A, Adams, GE & Stratford, IJ (1994). Factors affecting sensitivity to EO9 in rodent and human tumour cells in vivo: DT-diaphorase and hypoxia. Eur J Cancer 30A: 1013–1019.
Saunders, MP, Chinje, EC, Patterson, AV, Harris, AL & Stratford, IJ (1999). NADPH:cytochrome c (P450) reductase activates tirapazamine to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. (in press).
Seng, F & Ley, K (1972). Simple synthesis of 3-amino-1,24-benzotriazine-1,4-dioxide. Angew Chem Int XI: 1009–1010.
Siim, BG, Van Ziji, PL & Brown, JM (1996). Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 73: 952
Silva, JM & O’Brien, PJ (1993). Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. Br J Cancer 68: 484–491.
Smith, PK, Krohn, RI, Hermanson, GT, Mallia, AK, Gartner, FH, Provenzano, MD, Fujimoto, EK, Groeke, NM, Olaon, BJ & Klenk, DC (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76–85.
Stratford, IJ & Stephens, MA (1989). The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 16: 973–976.
Teicher, BA (1994). Hypoxia and drug resistance. Cancer and Metastasis Rev 13: 139–168.
Varnes, ME, Tuttle, SW & Biaglow, JE (1984). Nitroheterocycle metabolism in mammalian cells. Stimulation of the hexose monophosphate shunt. Biochem Pharmacol 33: 1671–1677.
Von Pawal, J & Von Roemeling, R (1998). Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT 1 trial. Proc Am Soc Clin Oncol 17: 454a
Walton, MI & Workman, P (1990). Enzymology of the reductive activation of SR 4233: a novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol 39: 1735–1742.
Walton, MI, Wolf, CR & Workman, P (1989). Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 16: 983–986.
Walton, MI, Wolf, CR & Workman, P (1992). The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1, 4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 44: 251–259.
Wang, J, Biedermann, KA & Brown, JM (1992). Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 52: 4473–4477.
Wang, J, Biedermann, KA, Wolf, CR & Brown, JM (1993). Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br J Cancer 67: 321–325.
Williams, CH Jr & Kamin, H (1962). Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem 237: 587–595.
Wouters, BG & Brown, JM (1997). Cells at intermediate oxygen levels can be more important than the ‘hypoxic fraction’ in determining tumor response to fractionated radiotherapy. Radiat Res 147: 541–550.
Zeman, EM, Brown, JM, Lemmon, MJ, Hirst, VK & Lee, WW (1986). SR4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239–1242.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Chinje, E., Patterson, A., Saunders, M. et al. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?. Br J Cancer 81, 1127–1133 (1999). https://doi.org/10.1038/sj.bjc.6690819
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690819
Keywords
This article is cited by
-
The chemical and biological activities of quinones: overview and implications in analytical detection
Phytochemistry Reviews (2011)
-
The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines
British Journal of Cancer (2005)